
Opinion|Videos|May 8, 2024
Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
3
Beyond Injections: The Rise of Oral GLP-1 Therapy
4
FDA Accepts NDA for Giredestrant in Early-Stage ER-Positive Breast Cancer Under Priority Review
5






















































































































